Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis

ObjectiveEfgartigimod (EFG), a neonatal Fc receptor antagonist that facilitates the degradation of pathogenic immunoglobulin G, is approved for the treatment of generalized myasthenia gravis (MG). This study aims to evaluate the efficacy and safety of EFG in patients with very-late-onset myasthenia...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Zhouyi Wang, Tiancheng Luo, Deyou Peng, Xue Du, Xiaoyu Huang, Yong Zhang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-04-01
סדרה:	Frontiers in Immunology
נושאים:	very-late-onset myasthenia gravis fast-acting treatment efgartigimod MG-ADL clinical meaningful improvement
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579859/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!